|Description||Albutrepenonacog alfa is a long-acting recombinant coagulation factor IX albumin fusion protein. It was approved for the treatment of hemophilia B. It can reduce the risk of bleeding episodes in patients with hemophilia B.|
|Brife Description||recombinant coagulation factor IX albumin fusion protein, hemophilia B|
|Application||the treatment of hemophilia B|
|Current Developer||CSL Behring|
L-alanosine is an amino acid analogue and antibiotic derived from the bacterium Streptomyces alanosinicus with antimetabolite and potential antineoplastic activ...
Extract from Carthamin, widely used for the treatment of acute ischemic stroke by acting directly on BV2 microglia.
L-p-Hydroxyphenyglycines a carnitine is a palmitoyltransferase-1 inhibitor, improves whole-body glucose tolerance and insulin sensitivity in high-fat diet-induc...
Valrubicin (AD-32) is a chemotherapy drug used to treat bladder cancer. It is a semisynthetic analog of the anthracycline doxorubicin, and is administered by in...
GSK-2269557 HCl salt
GSK-2269557 is a selective Phosphatidylinositol 3 kinase delta inhibitor originated by GlaxoSmithKline. GSK-2269557 is highly selective for PI3Kδ over the close...
Dolastatin 10 is an inhibitior of microtubule disassembly (IC50= 1.2μM) and potently inhibits vincristine binding to tubulin in a noncompetitive manner ( Ki= 1....
CHC is a monocarboxylic acid transport (MCT) inhibitor, displaying antitumoral and antiangiogenic activity in gliomas in vivo. It decreases glycolytic metabolis...
LY2608204 activates glucokinase (GK) with EC50 of 42 nM at 10 mM glucose with a concentration dependent manner at lower glucose concentrations.